
Canaccord lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $12 from $13 and keeps a Buy rating on the shares. The firm updated its model after the company
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics | 3.38 | 1.08 | 47.14% |
| Name | Price | % Change | |
|---|---|---|---|
| $3.38 | +47.14% |

Canaccord lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $12 from $13 and keeps a Buy rating on the shares. The firm updated its model after the company

Aclaris Therapeutics (ACRS) on Monday announced top line results from the Phase 2 ADMIRATION trial that evaluated the efficacy and safety of bosakitug, a humanized anti-thymic stromal lymphopoietin monoclonal antibody,

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral from Outperform with a price target of $3, down from $8, after the Phase 2 ADMIRATION trial of bosakitug for atopic dermatitis failed

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral from Outperform with a $3 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

An update from Aclaris Therapeutics ( ($ACRS) ) is now available. On November 16, 2026, Aclaris reported that its Phase 2 ADMIRATION trial of bosakitug in patients with moderate-to-severe atopic

Aclaris Therapeutics (ACRS) announced initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib in patients with moderate-to-severe lichen planus; the first cohort to be enrolled will be

Reports Q3 revenue $1.48M, consensus $1.23M. Believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the first half of 2029, without giving

Canaccord raised the firm’s price target on Aclaris Therapeutics (ACRS) to $13 from $10 and keeps a Buy rating on the shares. The firm said Aclaris reported positive data from

Craig-Hallum lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $9 from $10 and keeps a Buy rating on the shares following ATI-052’s POC data in atopic derm/asthma and

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aclaris Therapeutics and keeping the price target at $16.00. Ram Selvaraju has given his Buy rating due to a
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 25, 2027TBA | $571.80M | $-0.16 | $1.37M | 0.08 | -6.28 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.